（2024修订） 第一章 总则 第二章 募集资金的存储 第五条 募集资金到位后，公司应及时办理验资手续，并由董事会按照招股说 明书或募集说明书所承诺的募集资金使用计划，管理和使用募集资金。 蓝星安迪苏股份有限公司 募集资金使用管理办法 重要提示：若中文与英文版本有任何差异或不一致，以中文版本为准。 蓝星安迪苏股份有限公司 募集资金使用管理办法 第 1 页，共 9 页 第一条 为规范蓝星安迪苏股份有限公司（以下简称"公司"）募集资金的管理 和运用，保护投资者的利益，根据《中华人民共和国公司法》（以下 简称《公司法》）《中华人民共和国证券法》（以下简称《证券法》） 《上海证券交易所股票上市规则》（以下简称《股票上市规则》） 《上海证券交易所上市公司自律监管指引第1号——规范运作》《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《蓝星安迪苏股份有限公司章程》（以下简称《公司章程》）以及其 他相关法律、法规和规范性文件的规定，结合公司实际情况，特制定 《蓝星安迪苏股份有限公司募集资金使用管理办法》（以下简称"本制 度"）。 第二条 本制度所称募集资金是指公司通过发行股票及其衍生品种，向投资者 ...

证券代码：600299 证券简称：安迪苏 公告编号：2024-015 蓝星安迪苏股份有限公司 关于向特定对象发行 A 股股票预案披露的提示性公告 蓝星安迪苏股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第八届董事 会第十八次会议、第八届监事会第十二次会议，审议通过了关于公司向特定对象发行 股票的相关议案。具体内容详见公司同日刊载于上海证券交易所网站 （www.sse.com.cn）的《蓝星安迪苏股份有限公司向特定对象发行A股股票预案》及相 关文件。 本次预案的披露不代表审批机关对于本次向特定对象发行股票相关事项的实质性 判断、确认、批准或注册。预案所述本次向特定对象发行 A 股股票相关事项的生效和 完成尚需取得有权国有资产监督管理部门批准，公司股东大会审议通过、上海证券交 易所审核通过并取得中国证券监督管理委员会的同意注册等程序，敬请广大投资者注 意投资风险。 特此公告。 蓝星安迪苏股份有限公司董事会 2024 年 4 月 25 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [1][2] Core Views - The company's performance is gradually improving, supported by capacity expansion which aids growth [1][2] - In 2023, the company achieved revenue of 13.184 billion yuan, a year-on-year decrease of 9.26%, and a net profit attributable to shareholders of 52 million yuan, down 95.82% year-on-year [1][3] - Since the third quarter of 2023, market demand has been recovering slowly, leading to improved performance due to increased production, stable prices, and reduced raw material and energy costs [1][2] - The company has a rich product portfolio and is continuously expanding its capacity, with significant growth in specialty products driven by the aquaculture and new monogastric products [1][2] Summary by Sections Financial Performance - In 2023, the company's gross profit margin was 21.38%, a decrease of 6.13 percentage points year-on-year [1][3] - The fourth quarter of 2023 saw a significant improvement in net profit attributable to shareholders, reaching 87 million yuan [1] Capacity Expansion and Product Development - The company has successfully launched new production capacities, including a 180,000-ton liquid methionine plant in Nanjing and a 150,000-ton solid methionine plant in Quanzhou, expected to be operational by 2027 [1][2] - The company is focusing on research and innovation, with new product launches and strategic partnerships, such as the introduction of the DynOmik™ product in the U.S. market [2][3] Profit Forecast and Investment Recommendations - The forecast for net profit attributable to shareholders for 2024-2026 is 355 million, 745 million, and 1.046 billion yuan, respectively, with corresponding PE ratios of 69, 33, and 24 [2][3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [14]. Core Views - The company's performance in 2023 was significantly impacted by a decline in the prices of its main products and impairment provisions, leading to a 95.82% year-on-year drop in net profit [2][6]. - Despite the challenges, the company's profitability began to improve in the second half of 2023, driven by a rebound in methionine prices and increased sales volume [2][6]. - The company is expanding its production capacity, including a new solid methionine project in Quanzhou, which is expected to enhance its competitive advantage in the industry [7]. Financial Summary - In 2023, the company's operating revenue was 13,184 million yuan, a decrease of 9.3% year-on-year, while the net profit attributable to the parent company was 52 million yuan, down 95.82% [1][2]. - The company's cash flow from operating activities increased by 59.89% year-on-year, reaching 2,764 million yuan, due to strict cash and working capital management [2][9]. - The report projects future revenues and profits, estimating operating revenues of 13,789 million yuan, 14,831 million yuan, and 16,284 million yuan for 2024, 2025, and 2026 respectively, with net profits of 383 million yuan, 801 million yuan, and 1,093 million yuan for the same years [7][9]. Business Segments - The functional products segment experienced a revenue decline of approximately 15%, while the specialty products segment saw an 8% increase in revenue for the year [2][6]. - The gross margin for the specialty products business improved to 49% in Q4 2023, indicating a recovery in profitability [2][6]. - The company plans to permanently close its solid methionine production line in France to enhance overall cost competitiveness in its methionine business [7].

蓝星安迪苏股份有限公司 蓝星安迪苏股份有限公司 2023 年年度业绩投资者沟通会议记录 一、会议时间 2024 年 3 月 29 日 9:00-10:00 董事会秘书：蔡昀女士 四、会议地点 二、参与单位名称及人员姓名 部分参会机构名单详见附件清单。 重要提示：参会机构名单由组织机构提供并经整理后展示。公司无法保证 参会机构单位名称的完整性、准确性，敬请投资者注意。 三、公司接待人员 董事长兼总经理（CEO）：郝志刚先生 Teams 线上会议。 五、 主要内容 投资者交流会以线上交流互动形式召开，公司高管团队向投资者详细 介绍了公司 2023 年年度财务报告、经营情况、行业趋势、未来规划等。并 在信息披露允许的范围内就投资者普遍关注的问题进行回答。公司与投资 者主要沟通内容如下： 1 蓝星安迪苏股份有限公司 1. 公司产品蛋氨酸的产业链下游的需求情况及其占比？ 蛋氨酸市场是一个不断增长的市场，过去几十年一直非常稳定，这得 益于非常强大的基本面：人口、人均肉类消费和添加量等因素。长期来看， 蛋氨酸的基本面即经济可持续动物蛋白的需求将持续存在。到 2050 年，我 们需要以高质量、可负担、安全和可持续的方式供养超 ...

公 司 研 究 安迪苏（600299.SH）：业绩短期承 2024年3月29日 强烈推荐/维持 压，产能持续扩张巩固龙头地位 东 安迪苏 公司报告 兴 证 券 安迪苏发布2023年年报：全年实现营业收入为131.84亿元，YoY-9.26%，归 公司简介： 股 母净利润为0.52亿元，YoY-95.82%，EPS为0.02元。公司拟每10股派发现 安迪苏于 2006 年被中国蓝星集团收购，于 份 金红利0.6元（含税）。 2015 年借壳蓝星集团旗下的蓝星新材在 A 有 股上市。公司是全球第二大蛋氨酸生产商， 限 受到产品销售价格下滑，以及原材料、能源成本上升的双重挤压，公司业绩下 可同时提供固体蛋氨酸和液体蛋氨酸，是动 公 滑。从收入端看，2023年公司主要产品蛋氨酸市场均价同比2022年有所下滑， 物营养与健康行业的全球领军企业。 资料来源：公司公告、东兴证券研究所 司 导致公司营收小幅下滑。从利润端看，公司毛利率受到产品价格下滑的影响同 交易数据 比下滑7个百分点至21%，同时也受到资产减值和相关重组成本的影响（其中 证 券 主要由于 Commentry 固体蛋氨酸生产线，Innov’ia 的老旧工厂以 ...

Financial Performance - Net profit attributable to shareholders of the parent company for 2023 was RMB 52,165,518[4] - Cumulative distributable profit of the parent company as of December 31, 2023, was RMB 489,335,867[4] - Revenue in 2023 decreased by 9.26% year-on-year to RMB 13.18 billion, compared to RMB 14.53 billion in 2022[21] - Net profit attributable to shareholders dropped significantly by 95.82% to RMB 52.17 million in 2023, down from RMB 1.25 billion in 2022[21] - Basic earnings per share (EPS) fell by 95.65% to RMB 0.02 in 2023, compared to RMB 0.46 in 2022[22] - The weighted average return on equity (ROE) decreased by 8.36 percentage points to 0.35% in 2023[22] - Revenue for the period decreased by 9.26% to RMB 13,183,748,624 compared to the same period last year[54] - Gross profit margin for the nutrition and health industry decreased by 7 percentage points to 21%[56] - Functional products revenue decreased by 15% to RMB 8,807,341,566, with a gross margin reduction of 11 percentage points[56] - Special products revenue increased by 8% to RMB 3,593,810,639, but gross margin decreased by 4 percentage points[56] - Revenue in China increased by 11% to RMB 1,793,361,133, while other regions experienced declines[56] - Sales expenses increased by 5.49% to RMB 1,227,058,560, and management expenses rose by 9.84% to RMB 768,915,157[62] - R&D expenses increased by 18.17% to RMB 419,245,587, reflecting higher investment in innovation[54] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Total R&D investment in 2023 was RMB 518,242,447, accounting for 3.93% of total revenue, with 8.20% of R&D investment capitalized[63] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] - Total R&D expenditure in 2023 was RMB 518,242,447, accounting for 3.4% of net assets and 3.9% of operating revenue[84] - The total actual compensation paid to directors, supervisors, and senior management during the reporting period was RMB 52.44 million[153] - The company allocated a cash dividend of 404,967,092.22 yuan for 2022, representing 32.48% of the net profit attributable to shareholders[180] Profit Distribution and Dividends - Proposed cash dividend of RMB 0.6 per 10 shares, totaling RMB 160,914,076 (tax inclusive)[4] - The company plans to maintain the per-share distribution ratio and adjust the total distribution amount if the total share capital changes before the equity distribution record date[4] - The profit distribution plan is subject to approval at the 2023 Annual General Meeting of Shareholders[4] - The company's cash dividend policy mandates that at least 30% of the distributable profits be allocated as cash dividends when the company is profitable and has positive undistributed profits[180] Cash Flow and Working Capital Management - Operating cash flow increased by 59.89% to RMB 2.76 billion in 2023, driven by strict cash and working capital management[22] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 39.17 million in 2023, primarily due to government subsidies and asset disposal losses[25][26] Asset and Liability Management - Total assets increased slightly by 0.80% to RMB 21.51 billion at the end of 2023[21] - The company's net debt level decreased due to improved cash flow management[22] - Derivative financial assets increased by RMB 11.39 million, from RMB 4.88 million to RMB 16.28 million, impacting current profits by RMB 12.74 million[27] - Derivative financial liabilities decreased by RMB 354,904, from RMB 363,722 to RMB 8,818, impacting current profits by RMB -414,944[27] - Other equity instrument investments increased by RMB 15.15 million, from RMB 262.66 million to RMB 277.80 million[27] - Other non-current financial assets increased by RMB 33.15 million, from RMB 75.87 million to RMB 109.02 million, impacting current profits by RMB 27.84 million[27] - Total fair value changes amounted to RMB 60.05 million, with a total impact on current profits of RMB 40.16 million[27] - Overseas assets accounted for 55% of total assets, amounting to RMB 11,738,245,328, reflecting the company's global presence in animal nutrition additives[69] Environmental and Sustainability Goals - The company aims to reduce greenhouse gas emissions by 37% from 2020 to 2035 while maintaining business growth[30] - The company has already achieved its 2025 target of reducing greenhouse gas emissions, energy consumption, and water usage by 20% compared to 2025 levels[30] - The company has established a carbon reduction roadmap for 2050 in collaboration with a leading French sustainability consulting firm[30] - The company is committed to aligning its environmental goals with the Paris Agreement and the United Nations Framework Convention on Climate Change[30] - The company focuses on four key areas: reducing its own carbon footprint, contributing to reducing the carbon footprint across the value chain, ensuring responsible behavior towards employees and stakeholders, and enhancing governance and sustainability communication[30] - The company invested 23.38 million yuan in environmental protection during the reporting period[190] - The company's subsidiary, BlueStar Adisseo Nanjing Co., Ltd., maintained stable and compliant emissions of waste gas, wastewater, and noise in 2023[191] - The company's annual emissions of sulfur dioxide (SO2) were 3.65 tons, with an emission concentration of 1.148 mg/m³, well below the permitted limit of 200 mg/m³[192] - Nitrogen oxides (NOx) emissions totaled 134.47 tons annually, with an emission concentration of 53.04 mg/m³, within the permitted limits of 200-300 mg/m³[192] - Non-methane total hydrocarbon (NMHC) emissions were 4.149 tons annually, with an emission concentration of 1.25 mg/m³, significantly below the permitted limit of 80 mg/m³[193] - Chemical oxygen demand (COD) in wastewater was 44.11 tons annually, with a concentration of 122 mg/L, well below the permitted limit of 500 mg/L[194] - Ammonia nitrogen (NH3-N) in wastewater was 2.07 tons annually, with a concentration of 6.2 mg/L, significantly below the permitted limit of 45 mg/L[195] - Total suspended solids (SS) in wastewater were 10.96 tons annually, with a concentration of 31 mg/L, well below the permitted limit of 400 mg/L[195] - Five-day biochemical oxygen demand (BOD5) in wastewater was 12.84 tons annually, with a concentration of 36 mg/L, significantly below the permitted limit of 300 mg/L[195] - Total nitrogen (TN) in wastewater was 4.21 tons annually, with a concentration of 11.68 mg/L, well below the permitted limit of 70 mg/L[195] - Noise levels at the factory boundary were 59.98 dB(A) during the day and 52.29 dB(A) at night, both below the permitted limits of 65 dB(A) and 55 dB(A) respectively[195] - Hazardous waste generation in 2023 was 91,405.67 tons, with 91,002.95 tons processed internally and 402.73 tons transferred out[196] - The company completed the environmental online monitoring system for elevated flares in 2023 and connected it to the environmental protection department's platform[198] - The Nanjing factory's waste heat power generation project entered the testing phase in January 2024, aiming to utilize excess steam more effectively[198] - The acrylic acid wastewater treatment and reclaimed water reuse project is expected to start construction in 2024 and be operational by 2025, significantly reducing nitrogen oxide emissions and natural gas consumption[198] - The Nanjing factory passed the second round of clean production audit in February 2023, achieving the first level (international advanced level) of clean production[199] - The environmental protection acceptance of the Nanjing factory's second-phase project was completed on June 30, 2023[199] - The company completed two full-scale emergency drills for environmental incidents in 2023 and plans to continue drills in 2024 to enhance response capabilities[200] Production and Capacity Expansion - The company successfully increased annual production capacity by 80,000 tons through the expansion of European production platforms, including new production lines at Burgos and Les Roches factories[33] - The Nanjing liquid methionine plant (BANC2) reached a total capacity of 350,000 tons, making it one of the largest and most cost-competitive liquid methionine production platforms globally[33] - A new solid methionine plant with an annual capacity of 150,000 tons is planned in Quanzhou, expected to be operational by 2027[33] - The European production platform has successfully added 80,000 tons/year of liquid methionine capacity since Q3 2021, enhancing market competitiveness[36] - The Nanjing production platform's Phase II plant, with an annual capacity of 180,000 tons of liquid methionine, was completed and operational in September 2022[37] - A new solid methionine plant in Quanzhou, with an annual capacity of 150,000 tons, is planned to start production in 2027[37] - The company's market share of methionine increased from 24% to 27% between 2012 and 2017, maintaining a strong position in recent years[37] - The company decided not to restart the solid methionine production plant in Commentry in January 2024 to improve cost competitiveness[37] - The company holds approximately 20% of the global feed-grade Vitamin A production capacity[38] - Vitamin A prices dropped sharply from April 2022 due to a major producer's return to the market[38] - The company reduced Vitamin A production from Q4 2022 to optimize working capital management amid weak demand[38] - The company's global finished product transportation volume increased to 1.318 million tons in 2023, up from 1.098 million tons in 2022[80] - Anhui transported 103,000 tons of intermediate products using dedicated railway tank cars in 2023 for safety reasons[80] - The company's product portfolio includes methionine, vitamins, enzyme preparations, and other specialty products for animal feed applications[82] - The company's raw materials and finished products are stored in tanks and traditional warehouses, with unified management standards for both in-plant and off-plant warehouses[81] - The company's transportation strategy prioritizes safety, pollution reduction, and cost efficiency, with some routes adopting multimodal transportation to reduce carbon emissions[80] - The company's global market access planning enables precise technical specifications for each market, facilitating international business opportunities[82] - The company successfully obtained market access for its products in over 120 countries despite strict global trade measures and complex regulatory environments[83] - A new solid methionine plant in Quanzhou with a designed capacity of 150,000 tons/year is under construction, with an investment of RMB 170 million and expected completion in 2027[86][87] - The Nanjing plant's total capacity has been expanded to 350,000 tons/year after the completion of debottlenecking and liquid methionine phase II projects[88] - The company permanently closed the Commentry solid methionine production line in January 2024 to improve cost competitiveness[89] - Procurement costs for key raw materials decreased significantly: propylene (-17%), methanol (-14%), and sulfur (-43%)[90] - Energy procurement costs also decreased: natural gas (-33%) and electricity (-29%)[91] - The company uses derivative financial instruments to manage currency exchange rate risks, primarily through cash flow hedging[95][96] - Direct sales through the company's own network account for over 85% of total sales, with the remainder through distributors[94] Product Development and Innovation - A new product, DynOmik™, was launched in the US market in Q3 2023, aimed at improving milk production efficiency and sustainability[33] - The company's specialty products business achieved continuous revenue growth, driven by growth in aquatic and monogastric products, despite weak demand in the US and China dairy markets[33] - The company's joint venture, Kaidi Su, entered trial production and signed a strategic cooperation agreement with a leading Chinese feed producer for its innovative single-cell protein product[33] - The company launched a new technical service, Nestor, in Q3 2022, which has been widely adopted by key clients for feed formulation optimization[34] - DynOmik™, a new ruminant additive product, was fully launched in the North American market after its initial release in two US states in Q3 2023[34] - The company's R&D efforts are focused on five pillars: green production, new testing, multi-dimensional impact, innovation synergy, and digital empowerment[33] - The company's new R&D center in Lyon, operational in Q4 2023, integrates chemical, engineering, nutritional, and analytical capabilities[34] - The company launched DynOmik™ in the US in 2023, the first solution to increase milk production while reducing methane emissions in cows[51] - Adisseo's Rovabio Phyplus, the latest generation of phytase, improves overall nutritional efficiency, sustainability, and feed digestibility[51] - Adisseo established the "Sinochem Animal Nutrition Center Research Institute" in early 2023, strengthening collaborations with international labs, universities, and research institutions[50] - Adisseo's innovation lab focuses on disruptive technologies, products, and services to enhance customer productivity, sustainability, and animal health[46] - Adisseo's dual-pillar strategy includes maintaining leadership in the methionine market and accelerating the development of specialty product business[47] - The company's R&D investment in 2023 increased significantly compared to 2022, driven by increased project investments, with strategic collaborations established with universities and research institutions in Europe, China, and Singapore[66] - The company has 4 R&D centers and 2 experimental stations globally, focusing on areas such as biotechnology, chemical processes, and smart agriculture[84] - The company's long-term performance evaluation standards focus on sustainable shareholder value creation, including total shareholder return and profitability growth[176] - The company emphasizes the relationship between individual and organizational performance in determining executive compensation[177] Market and Competitive Position - The company's performance improved in the second half of 2023, with Q4 revenue reaching RMB 3.57 billion, the highest among all quarters[24] - Asset impairments and restructuring costs, particularly related to the closure of the Commentry solid methionine production line and Innov'ia plant, significantly impacted profitability[22] - The company's liquid methionine technology and cost leadership position it as one of the lowest-cost producers globally, with significant barriers to entry in the methionine market[72] - The animal feed additive industry is expected to grow due to global trends such as meat industrialization, population growth, and sustainable development, with emerging markets shifting towards protein-rich diets[72] - In 2023, the company's operating performance improved due to increased production, stable prices, reduced raw material and energy costs, and profit protection measures, despite challenges in the macroeconomic environment[72] - Anhui's global market leadership in methionine was consolidated in 2023 due to successful marketing and completion of expansion and debottlenecking projects in Europe and China[73] - Anhui decided to stop exporting solid methionine from France to the US and redirect limited products to other regions and countries[73] - Anhui permanently closed a solid methionine production line in Europe and adjusted liquid methionine production to mitigate the impact of global demand slowdown in 2023[73] - Anhui's vitamin business profitability stabilized in 2023 despite significant price pressure, benefiting from prudent production and price management[74] - The company faces competition from large, well-funded companies and new entrants, with strategies including cost control, process improvements, and capacity expansion in China and Europe[112] - Risks related to product development and technological advancements, particularly in methionine production, could impact competitiveness if competitors achieve breakthroughs first[114] Risk Management - The Russia-Ukraine conflict and Red Sea ship attacks have increased uncertainty, potentially leading to supply disruptions and higher costs for raw materials and energy[107] - The company faces risks from global macroeconomic fluctuations, serving over 4,200 customers in more than 110 countries[111] - Key raw materials such as acrylic, sulfur, methanol, ammonia, and natural gas are sourced from a limited number of suppliers, with potential risks from price volatility and supply disruptions[113] - The company is exposed to currency exchange risks due to operations primarily in euros and dollars, while financial statements are consolidated in RMB[116] - Compliance risks include potential violations of anti-corruption, antitrust, and international sanctions regulations, with extensive employee training programs in place to mitigate these risks[108] - Environmental regulations and potential changes in emission standards could require additional investments in sustainability and environmental facilities[109] - Tax and tariff risks include potential increases in effective tax rates due to changes in local tax laws and geopolitical tensions affecting import regulations[118] - Industrial risks include potential damage to individuals, property, or the environment, with some facilities classified as "highest level" chemical bases under EU directives[119] - Production involves hazardous chemicals and complex processes, with risks of leaks, emissions, and waste exceeding standards, potentially leading to civil, criminal, and financial liabilities[120] - Disease outbreaks (e.g., avian flu, African swine fever) and production accidents could significantly impact livestock numbers, consumer demand, and the company's financial performance[121] - Mismanagement of production plans, equipment failures, or overestimation of market demand could harm customer relationships and future sales[122] - Increasing cybersecurity threats, including phishing, hacking, and malware, pose risks to IT systems and data, potentially causing operational disruptions and reputational damage

蓝星安迪苏股份有限公司 董事会审计、风险及合规委员会 2023 年度履职报告 （2）向董事会提出聘请审计机构的建议 一．审计委员会基本情况介绍 2021 年 9 月，经第八届董事会第一次会议选举，第八届审计委员会成员原为：丁 远（主席），伍京皖和 Caroline Grégoire Sainte-Marie。其中，伍京皖先生自 2023 年 10 月 27 日起辞去公司董事（包括审计委员会成员）职务。经 2023 年 10 月 27 日召开的第 八届董事会第十三次会议及 2023 年 12 月 11 日召开的临时股东大会审议通过，孙岩峰 先生自 2023 年 12 月 11 日起任审计委员会成员。 审计委员会的组成与运行符合上海证券交易所的相关规定及《公司章程》和《审 计、风险及合规委员会实施细则》等制度的有关要求。 报告期内，审计委员会共召开 7 次会议，以下是具体内容： 召开日期 会议届次 会议议案 2023 年 2 月 15 日 第八届董事会审计、风 险及合规委员会第九次 会议 讨论了： 1. 2022 年业绩快报。 2023 年 3 月 28 日 第八届董事会审计、风 险及合规委员会第十次 会议 审议 ...

蓝星安迪苏股份有限公司 关于 2023 年度利润分配方案的公告 证券代码：600299 证券简称：安迪苏 公告编号：2024-006 监事会认为，公司的利润分配符合有关法律法规和《公司章程》的规定，充 分考虑了全体股东的利益，符合公司实际情况，未有损害公司和股东利益的情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 经毕马威华振会计师事务所（特殊普通合伙）审计，蓝星安迪苏股份有限公 司（简称"安迪苏"或"公司"）2023 年度合并层面实现归属于上市公司股东的 净利润为人民币 52,165,518 元，安迪苏母公司层面截至 2023 年 12 月 31 日累计可 供分配利润为人民币 489,335,867 元。 为了与全体股东分享公司业绩成果，同时促进公司进一步发展，董事会在充 分考虑公司实际运营情况的基础上，建议以实施权益分派股权登记日的总股本为 基础，向全体股东每 10股派发现金股利 0.6元人民币（含税），预计总额为人民币 160,914,076 元人民币（含税）。本年度公司现金分红比例为年度归属于上市公司 ...

蓝星安迪苏股份有限公司 内部控制审计报告 2023 年 12 月 31 日 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码 : 100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见,并 对注意到的非财务报告内部控制的重大缺陷进行披露。 KPMG Huazhen LLP, a People's Re ...